>> 1.      I assumed that the survey was referring to AS/400 Basic,

I only hope you are wrong Al because AS/400 Basic already has problems running
on current releases and it is only likely to get worse. Part of my comment was
aimed at making sure people were aware of that.  PL/I is a little different in
that IBM has at least got some incentive to make it work since some large
software vendors (e.g. the company formally know as Synon) still have software
out there built with it.  They have _no_ such incentive to keep Basic working.

 >> 2.      I suspect that even IBM is not stupid enough to pull support for RPG
III anytime soon.

I agree that it is unlikely in the short/medium term. I do not think that it
would be "stupid" to announce an end-date for support, like Office Vision it
might be stupid to try to stick to the date, but..... I have met so many people
who want to use RPG IV because they recognize the benefits, but their management
will not permit them to do so all the time RPG/400 is still supported. George
Farr did reportedly announce the death of RPG/400 at COMMON in San Antonio!!

At least many of the middle tier software vendors have woken up and started
developing/shipping RPG IV based product now. If you are building a new version
of a package (with the resultant testing requirements) you have to be nuts _not_
to switch while you're doing it.



+---
| This is the Midrange System Mailing List!
| To submit a new message, send your mail to MIDRANGE-L@midrange.com.
| To subscribe to this list send email to MIDRANGE-L-SUB@midrange.com.
| To unsubscribe from this list send email to MIDRANGE-L-UNSUB@midrange.com.
| Questions should be directed to the list owner/operator: david@midrange.com
+---

This thread ...

Follow-Ups:

Follow On AppleNews
Return to Archive home page | Return to MIDRANGE.COM home page

This mailing list archive is Copyright 1997-2020 by midrange.com and David Gibbs as a compilation work. Use of the archive is restricted to research of a business or technical nature. Any other uses are prohibited. Full details are available on our policy page. If you have questions about this, please contact [javascript protected email address].